Newsletter – November 2019
 |
NEWSLETTER NOVEMBER 2019CLINICAL TRIAL NEWS |
Take a Break and Read our Clinical Trial News!
|
|
|
|
 |
USING DISEASE FREE SURVIVAL (DFS) AS A PRIMARY ENDPOINT IN EARLY BREAST CANCER
IDDI in collaboration with Roche have identified why using disease-free survival as a primary endpoint in early breast cancer is the way forward! |
 |
BAYESIAN OUTCOME-ADAPTIVE RANDOMIZATION DESIGNS: A PROMISE NOT WITHOUT PERIL
Learn on the principles of OAR designs – The key considerations for implementing Bayesian OAR designs and potential challenges ahead – The impact of selected elements of OAR designs on operational characteristics of a clinical trial – The advantages and disadvantages of OAR designs. |
| TALENT SPOTLIGHT | |
 |
Elisabeth (Els) Coart, M.Sc, PhD, Director, Consulting Services
Els joined IDDI in 2011, initially for research work related to biomarkers in Alzheimer’s disease. She has a strong background in assay development combined with 10 years’ experience as statistician for biotech and diagnostic industries. Over the past several years, Els has gained comprehensive experience in study design for oncology and has become IDDI’s expert in analytical and clinical validation of (companion) diagnostics, or IVDs. She has represented IDDI in symposia, publications, and countless interactions with prospects and clients. Els shares her high level of expertise with our team of consultants and has been instrumental in making this team grow over the last couple of years. |
| FAST GROWING COMPANY | |
 |
OPENING OF A SECOND EUROPEAN OFFICE
IDDI has opened a new office in Mont-Saint-Guibert, Belgium to accommodate accelerated growth. This new location houses up to 40 additional employees. |
 |
MORE THAN 20 NEW EMPLOYEES SINCE BEGINNING OF THE YEAR
Interested in joining us? View our career page! Tremendous opportunities in Belgium and in the US. Apply today! |
| UPCOMING EVENTS
We look forward to meeting you at one of those following events! |
|
|
|
| |
COMBINING PASSION SCIENCE AND EXPERIENCE TO ENSURE YOUR CLINICAL DATA IS READY FOR SUBMISSIONIDDI is a biostatistical and eClinical services provider offering Trial Design – Randomization – Data Management and Biostatistics services for Pharmaceutical and Biotech companies. |
| IDDI (International Drug Development Institute) Serge Bodart – Chief Commercial Officer serge.bodart@iddi.signalsuite.com Direct: +1 514 909 0134 – +32 10 62 15 01 |
|